Medicine News Car T Cell Therapy Reaches Beyond Cancer Penn Medicine

From blood to solid tumors: A new way to power up CAR T cell therapy

T cell therapies have revolutionized cancer treatment—but so far, their success has been largely limited to blood cancers. Solid tumors, which account for around 90% of all adult cancers, remain a ... Read More

Optimizing CAR T Manufacturing With Automation and Global Networks

CAR T and CAR Treg therapies revolutionize cancer treatment through automation, scalability, and global manufacturing innovation. Read More

Next-generation CAR T cells could expand solid cancer treatment options

Chimeric antigen receptor (CAR) T cell therapy, which uses a patient's own immune cells to fight cancer, has emerged as a powerful way to treat lymphoma and other blood cancers. But researchers have ... Read More

New ‘plug-and-play’ cell design could revolutionize cancer immunotherapy

To make the therapy safer and more adaptable, UChicago researchers developed a new “split” system called GA1CAR. This uses engineered immune cells with a docking site that can receive updated tumor ... Read More

Penn professor Carl June discusses medical innovation award, CAR-T cell research in DP interview

Penn Medicine professor Carl June was recently awarded the Broermann Medical Innovation Award 2025 for his work on utilizing CAR-T cells in cancer therapy. Modifying T-cells with chimeric antigen ... Read More

Mount Sinai researchers pioneer first targeted therapy for rare T-cell lymphoma after CAR T treatment

New York, NY (August 21, 2025) – A team of researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai has successfully treated a rare and aggressive T-cell lymphoma ... Read More

How In Vivo CAR T-Cell Therapies Could Rewrite the Cancer Care Playbook

In vivo CAR T-cell therapies could improve access by eliminating complex logistics and reducing costs, making them more accessible to underserved populations. Traditional CAR T-cell therapies face ... Read More

Inhibiting a problematic protein helps immunotherapies, CAR T-cell therapy to fight off melanoma more effectively

The first-of-its-kind study shows that adding a small molecule that blocks the problematic protein to existing cancer treatments—like immunotherapy and CAR T-cell therapy—could help these treatments ... Read More

MagicRNA's First-in-Human Clinical Data Demonstrating Feasibility of In Vivo CAR T Therapy in Systemic Lupus Erythematosus Published in The New England Journal of Medicine.

SHENZHEN, China, Sept. 17, 2025 /PRNewswire/ -- MagicRNA, a clinical-stage biotechnology company pioneering in vivo CAR T-cell therapies, today announced the publication of the world's first clinical ... Read More